Abraxane shows potential in Phase I/II trial

The published results of a Phase I/II trial of Abraxane(paclitaxel albumin-bound particles for injectable suspension) in combination with gemcitabine in advanced pancreatic cancer patients has shown that this treatment shows potential for improving outcomes.

This treatment is being investigated further in an an ongoing, international, randomized phase III trial of Abraxane + gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer. The study is recruiting a large sample (842 people) across 152 sites, but unfortunately is not running in the UK.

For more information http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle_print&ID=1614329&highlight=

Anna